erythropoietin + granulocyte colony-stimulating factor

erythropoietin + granulocyte colony-stimulating factor refers to the therapeutic co-administration of erythropoietic and granulopoietic growth factors, a strategy specifically evaluated by **Weill Medical College of Cornell University** in clinical research. This combination was the focus of a Phase 4 trial (NCT00119132) aimed at managing hematologic side effects in patients coinfected with HIV and Chronic Hepatitis C who were receiving pegylated interferon and ribavirin. Erythropoietin functions by binding to and activating the erythropoietin receptor on erythroid progenitor cells, thereby stimulating erythropoiesis and increasing hemoglobin levels. G-CSF (Granulocyte Colony-Stimulating Factor) acts on the G-CSF receptor to promote the proliferation, differentiation, and survival of cells in the neutrophil lineage. By addressing both anemia and neutropenia, this dual growth factor support strategy is designed to prevent the need for antiviral dose reductions, potentially improving treatment outcomes for viral infections.

Other names

erythropoietin + G-CSFEPO + G-CSFGrowth Factor Support